TuHURA Biosciences Draws $650K from $50M Revolving Credit Facility

What Happened
TuHURA Biosciences, Inc. filed an 8‑K (dated August 21, 2026) reporting that it drew an additional $650,000 under a revolving Loan Agreement with Parkview Holdings One LLC. The Loan Agreement, originally entered April 21, 2026, provides up to $50 million in revolving credit and matures on April 21, 2031. The company said the $650,000 was received on August 20, 2026 and is expected to be used for general corporate purposes.

Key Details

• Loan Agreement counterparty: Parkview Holdings One LLC.
• Original agreement date: April 21, 2026; maturity date: April 21, 2031.
• Facility size: up to $50,000,000 of revolving loan availability.
• Recent draw: $650,000 received and borrowed on August 20, 2026.
• Filing: Current Report on Form 8‑K filed August 21, 2026, signed by CFO Dan Dearborn.
• The company included standard forward‑looking statement caution and noted risks including potential inability to draw funds, insufficient availability to fund operations, and possible conflicts of interest with an affiliate of its largest stockholder.

Why It Matters
This filing shows TuHURA is using its credit facility to raise near‑term cash for operations. For investors, the draw confirms access to external funding but also highlights reliance on debt and the need to manage capital resources. The disclosure of risks (including potential limits on future draws and related‑party considerations) is important context for assessing the company’s liquidity and financing strategy.